| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 益泽康瑞医药(香港)有限公司 | 0 | 49.70% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO was met with overwhelming demand, achieving an oversubscription ratio of 743.78x. The hit rate of just 20.95% underscores intense competition for allocations. Clawback C triggered significant reallocation to the public tranche, reflecting strong retail interest. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier distribution data is not provided, precluding analysis of allocation anomalies or broker fee efficiency. Without detailed subscription figures by tier, no pattern can be observed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographic breakdowns are entirely missing from the dataset, with holder counts and regional percentages set to zero. It is unclear whether mainland or local participation drove the demand. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Pegbio Co-B (02565): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

